|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 C
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 F
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 3
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 I
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 4
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 L
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 5
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 O
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 6
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 R
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 7
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 U
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
5OO6
Complex of human nuclear cap-binding complex with ARS2 C-terminal peptide
提交 2017-08-06
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验环境不同
结构质量不同
|
Assembly 8
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 X
827–871(45 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 5;293 K;CBC was mixed with an access of ARS2(827-871) in the presence of 1 mM m7GTP and subjected to gel filtration (120 mM NaCl, 5 mM beta-mercaptoethanol, 20 mM HEPES pH 7.8). The complex was concentrated to 8 mg/ml. Crystals were obtained in mother liquor containing 0.1 M sodium acetate pH 5, 8% (v/v) MPD and 0.1 M guanidine hydrochloride at 20 C.
|
分辨率 2.80 Å
R-free 0.268
|
|
6F7J
Crystal structure of Human ARS2 residues 171-270 + 408-763
提交 2017-12-10
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
171–270(100 aa)
链 B
408–763(356 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 10.5;281 K;Protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8, mixed 1:1 with reservoir solution containing 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate and 0.1 M CAPS pH 10.5.
|
分辨率 3.22 Å
R-free 0.322
|
|
6F7P
Crystal structure of Human ARS2 residues 147-270 + 408-763
提交 2017-12-11
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
147–270(124 aa)
链 C
408–763(356 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7.8;281 K;Crystals were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M lithium sulphate and 20% (w/v) PEG 3550.
|
分辨率 3.70 Å
R-free 0.309
|
|
6F7P
Crystal structure of Human ARS2 residues 147-270 + 408-763
提交 2017-12-11
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 B
147–270(124 aa)
链 D
408–763(356 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP;pH 7.8;281 K;Crystals were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution at 6 mg per ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 0.2 M lithium sulphate and 20% (w/v) PEG 3550.
|
分辨率 3.70 Å
R-free 0.309
|
|
6F8D
Crystal structure of Human ARS2 residues 171-270 + 408-763 (P65 form)
提交 2017-12-13
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 A
171–270(100 aa)
链 C
408–763(356 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 10.5;277 K;Crystals of ARS2 were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution (6 mg/ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate, 0.1 M CAPS pH 10.5
|
分辨率 3.48 Å
R-free 0.292
|
|
6F8D
Crystal structure of Human ARS2 residues 171-270 + 408-763 (P65 form)
提交 2017-12-13
|
构建体不同
突变/修饰不同
实验环境不同
结构质量不同
|
Assembly 2
蛋白同源多聚体
同源多聚体;蛋白 × 2
PDB 声明:dimeric
|
链 B
171–270(100 aa)
链 D
408–763(356 aa)
|
未记录
|
未记录非水小分子
|
X-RAY DIFFRACTION
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP;pH 10.5;277 K;Crystals of ARS2 were obtained at 4 C in 2 microlitre hanging drops with a 1:1 ratio of protein solution (6 mg/ml in 20 mM HEPES, 300 mM NaCl, 2 mM tris(2-carboxyethyl)phosphine pH 7.8) to crystallisation solution. The crystallisation solution was 1.2 M sodium dihydrogen phosphate, 0.8 M dipotassium hydrogen phosphate, 0.2 M lithium sulphate, 0.1 M CAPS pH 10.5
|
分辨率 3.48 Å
R-free 0.292
|
|
8PMP
Structure of the human nuclear cap-binding complex bound to ARS2[147-871] and m7GTP
提交 2023-06-29
|
构建体不同
突变/修饰不同
聚集状态不同
配体/离子不同
实验方法不同
实验环境不同
结构质量不同
|
Assembly 1
蛋白异源复合物
异源复合物;蛋白 × 3
PDB 声明:trimeric
|
链 D
148–876(729 aa)
|
未记录
|
MGT 7N-METHYL-8-HYDROGUANOSINE-5'-TRIPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM缓冲液
pH 8
cryo-EM玻璃化条件
冷冻剂 ETHANE
|
分辨率 3.43 Å
|